Where are you?
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
USA
International
Media & Investors
Transparency is key at Kuros Biosciences. Explore essential information – from corporate documents to our current share price, all in one place.
Press releases
Here are our latest press releases.
For archived news items, please go to our Resources center. To subscribe to receive our press releases, please click here.
10 Oct 2024
Adhoc Press Release
Kuros reports 149% increase in direct MagnetOs sales and exceeds cash flow breakeven in the first nine months of 2024
25 Jun 2024
Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft
Investor calendar
| Date | Event |
|---|---|
| Mar 11, 2025 | Earnings Release FY 2024 |
| Mar 11, 2025 | Investor Webcast FY 2024 (3pm CET) |
| Apr 15, 2025 | Annual Shareholders’ Meeting 2025 |
| Apr 17, 2025 | Trading Update Q1 2025 |
| Aug 13, 2025 | Earnings Release HY1 2025 |
| Aug 14, 2025 | Investor Webcast HY1 2025 (3pm CET) |
| Oct 16, 2025 | Trading Update Q3 2025 |
Reports, Corporate Governance & Meetings
Kuros Biosciences is fully committed to good corporate governance and adherence to high ethical standards. Our principles and rules on corporate governance and ethical conduct are articulated in the Articles of Association, the Internal Regulations, the charters of the committees of our board of directors, and our code of conduct.
Analysts
For more information regarding analyst reports, please contact:
Laura Pfeifer-Rossi
Octavian AG
sales@octavian.ch
Tel: +41 44 520 1588
Investor Relations
For more information regarding investor
relations, please contact:
Alexandre Müller
Kuros Biosciences
Investor Relations
IR@kurosbio.com
Tel: +41 43 268 32 31
Want to receive our press releases?